The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NovoCure's share price is $17.35.
NovoCure's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $4.81. Hence, NovoCure's PS Ratio for today is 3.60.
Good Sign:
NovoCure Ltd stock PS Ratio (=3.6) is close to 10-year low of 3.6
The historical rank and industry rank for NovoCure's PS Ratio or its related term are showing as below:
NVCR'
s PS Ratio Range Over the Past 10 Years
Min: 3.6 Med: 16.25 Max: 88.85
Current: 3.6
During the past 10 years, NovoCure's highest PS Ratio was 88.85. The lowest was 3.60. And the median was 16.25.
NVCR's PS Ratio is ranked worse than 51.47% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.51
vs NVCR: 3.60
NovoCure's Revenue per Sharefor the
three
months ended in Jun. 2023 was $1.19.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $4.81.
Warning Sign:
NovoCure Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of NovoCure was -8.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.80% per year.
During the past 10 years, NovoCure's highest 3-Year average Revenue per Share Growth Rate was 110.30% per year. The lowest was 12.50% per year. And the median was 35.40% per year.
Back to Basics: PS Ratio
NovoCure PS Ratio Historical Data
The historical data trend for NovoCure's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
PS Ratio
12.40
23.32
38.11
14.51
14.27
NovoCure Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
PS Ratio
13.27
14.62
14.27
12.09
8.62
Competitive Comparison
For the Medical Devices subindustry, NovoCure's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure PS Ratio Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's PS Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's PS Ratio falls in comparison to its industry or sector. The grey bar indicates the PS Ratio's extreme value range as defined by GuruFocus.
NovoCure PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NovoCure's Share Price of today is $17.35.
NovoCure's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.81.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NovoCure PS Ratio Related Terms
Thank you for viewing the detailed overview of NovoCure's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
0.24(1.36%) Volume: 1,039,175 11:09PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NVCR has been successfully added to your 
